Cerebroprotective effects of xanthohumol on experimental stroke model: study design and preliminary results
Year: 2020, volume 16 Issue: №1 Pages: 377-379
Heading: Neurology Article type: Original article
Authors: Saitgareeva A.R., Akhmadeeva L.R.
Organization: Bashkir State Medical University of the Russian Health Care
Heading: Neurology Article type: Original article
Authors: Saitgareeva A.R., Akhmadeeva L.R.
Organization: Bashkir State Medical University of the Russian Health Care
Summary:
The aim of the study is to evaluate the neuroprotective effect of xanthohumol (XN) on experimental models of acute ischemic stroke in vivo and in vitro. Material and Methods. Middle cerebral artery occlusion (MCAO) and oxygen-glucose deprivation (OGD) are used as an in vivo and in vitro model. The object of the study is Sprag-Dawley rats, which are randomly divided into three groups: a control group; two groups operated by MCAO with and without XN. Primary culture of cortical neurons was obtained from newborn rats. We use the Bederson test and the angle test to evaluate neurological disorders. Results. Preliminary results indicate a possible cerebroprotective effect of XN in an ischemic stroke model. Conclusion. Prophylactic administration of xanthohumol before cerebral ischemia in an experiment can effectively reduce the volume of cerebral infarction and improve neurological deficiency 24 hours after MCAO
Bibliography:
1. O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016; (388): 761-75.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; (380): 2095-128.
3. Mendis S, Davis S, Norrving B. Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke 2015; (46):e121-2.
4. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; (327): 656-61.
5. Elali A. The implication of neurovascular unit signaling in controlling the subtle balance between injury and repair following ischemic stroke. Neural Regen Res 2016; (11): 914-5.
6. Lo EH. A new penumbra: Transitioning from injury into repair after stroke. Nat Med 2008; (14): 497-500.
7. Verzele M, Stockx J, Fontijn F, Anteunis M. Xanthohumol, a new natural chalkone. J Agric Food Chem 1957; (66): 452-75.
8. Liu M, Hansen PE, Wang G, et al. Pharmacological profile of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus). Molecules 2015; (20): 754-79.
9. Zanoli P, Zavatti M. Pharmacognosticand pharmacological profile of Humulus lupulus L. J Ethnopharmacol 2008; (116): 383-96.
10. Xuan NT, Shumilina E, Gulbins EGu, et al. Triggering of dendritic cell apoptosis by xanthohumol. Mol Nutr Food Res 2010; 54 (Suppl. 2): 214-24.
11. Chen B, Zhang F, Li QY et al Protective Effect of Ad-VEGF-Bone Mesenchymal Stem Cells on Cerebral Infarction. Turk Neurosurg 2016; (26): 8-15.
12. Bederson JB, Pitts LH, Tsuji M, et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986; (17): 472-6.
13. Qu Y, Mao M, Zhao F, et al. Proapoptotic role of human growth and transformation-dependent protein in the developing rat brain after hypoxia-ischemia. Stroke 2009; (40): 2843-8.
14. Ginsberg MD, Busto R. Rodent models of cerebral ischemia. Stroke 1989, (20): 1627-42.
15. ladecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 2011; (17): 796-808.
16. Li F, Yao Y, Huang H, et al. Xanthohumol attenuates cisplatin-induced nephrotoxicity through inhibiting NF-кВ and activating Nrf2 signaling pathways. Int Immunopharmacol 2018; (61): 277-82.
| Attachment | Size |
|---|---|
| 2020_01-3_377-379.pdf | 351.45 KB |
Русский
English